310872-38-9

Upstream product

• 310872-33-4 (3aR,4S,5aS,8aR,8bR)-2,2,7,7-Tetramethyl-hexahydro-benzo[1,2-d;3,4-d']bis[1,3]dioxol-4-ol 
• 310872-36-7 (1R,2R,3S,4S)-3,4-Bis-benzyloxy-cyclohexane-1,2-diol 
• 310872-34-5 (3aR,5aS,8aR,8bR)-2,2,7,7-Tetramethyl-hexahydro-benzo[1,2-d;3,4-d']bis[1,3]dioxole 
• 310872-35-6 (3aS,4R,5S,7aR)-2,2-Dimethyl-hexahydro-benzo[1,3]dioxole-4,5-diol 
• 17230-47-6 (-)-Proto-quercitol-pentabenzoat 
• 17278-12-5 D-1,3,4/2,5-cyclohexanepentol 
• 100-39-0 benzyl bromide 
• 310872-37-8 (1R,2R,3R,4S)-2-Allyloxy-3,4-bis-benzyloxy-cyclohexanol 

Downstream Products

• 310872-39-0 (1R,2S,3S,6R)-2,3,6-Tris-benzyloxy-cyclohexanol 
• 310872-40-3 Phosphoric acid benzyl ester (R)-2-methoxy-3-octadecyloxy-propyl ester (1R,2R,3S,6R)-2,3,6-tris-benzyloxy-cyclohexyl ester 

Relevant academic research and scientific papers

Synthesis and Akt inhibitory properties of a 1D-3,4-dideoxyphosphatidylinositol ether lipid

1D-3,4-Dideoxyphosphatidylinositol ether lipid 2, a PI analog, was synthesized through a sequence of protection/deprotection protocols and two Barton deoxygenation reactions, starting from L-(-)-quebrachitol. DDPIEL is 18-fold more potent than its monodeoxy counterpart DPIEL in the inhibition of PI3-K. (C) 2000 Published by Elsevier Science Ltd.